TSX: CPH 12.36 +0.58 +4.92% Volume: 98,361 March 27, 2015
NASDAQ: CPHR 9.88 +0.45 +4.72% Volume: 1,759 March 27, 2015

Cipher Pharmaceuticals is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules.

Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was launched in the United States in Q4 2012 as Absorica™. The product was also recently launched in Canada as Epuris®.